文献速递乳腺癌支持与姑息治疗

CYP2D6基因型预测他莫昔芬停药与药物反应:KARISMA试验二次分析

CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.
PubMed 文献 · Ann Oncol · 2021-07-18

本研究基于KARISMA剂量确定试验中1440名健康女性的数据,分析CYP2D6代谢状态与他莫昔芬相关内分泌症状、停药及乳腺X线密度变化的关系。结果显示,弱代谢者他莫昔芬反应可能受损(乳腺密度下降较少),而超快代谢者不良反应更明显、6个月停药率更高(44.4%)。

要点

  • 弱代谢者乳腺密度下降较少,提示他莫昔芬反应可能受损。
  • 超快代谢者内分泌症状更明显,6个月停药率达44.4%。
  • CYP2D6代谢状态或可用于他莫昔芬个体化用药评估。

核心结论

  • 弱代谢者经乳腺X线密度下降评估的他莫昔芬反应可能受损。
  • 超快代谢者存在反应过度伴明显不良反应的风险,可能导致治疗中断。

研究设计与样本

  • KARISMA剂量确定试验的二次分析,纳入1440名健康女性。
  • 参与者经基因分型分为弱、中间、正常和超快CYP2D6代谢者。
  • 内分泌症状采用改良FACT-ES问卷评估,乳腺X线密度变化作为他莫昔芬反应的替代指标。

主要发现

  • 弱、中间、正常和超快代谢者每毫克口服他莫昔芬的Endoxifen中位水平分别为0.18 ng/ml、0.38 ng/ml、0.56 ng/ml和0.67 ng/ml。
  • 超快代谢者较其他组更易报告冷汗、潮热、情绪波动、易怒及改良FACT-ES总评分的临床相关变化。
  • 弱、中间、正常和超快代谢者的6个月他莫昔芬停药率分别为25.7%、23.6%、28.6%和44.4%。
  • 完成6个月他莫昔芬干预者中,弱、中间、正常和超快代谢者的致密面积平均变化分别为-0.8 cm2、-4.5 cm2、-4.1 cm2和-8.0 cm2。

临床怎么用

  • 对他莫昔芬治疗者可考虑CYP2D6基因分型以评估反应与不良反应风险。
  • 超快代谢者需关注内分泌症状并加强依从性管理以降低停药风险。
  • 弱代谢者可能反应不足,需评估替代内分泌治疗策略。

局限性

  • 为KARISMA试验的二次分析,研究对象为健康女性而非乳腺癌患者。
  • 乳腺X线密度变化仅为他莫昔芬反应的替代指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Guidelines regarding whether tamoxifen should be prescribed based on women's cytochrome P450 2D6 (CYP2D6) genotypes are conflicting and have caused confusion. This study aims to investigate if CYP2D6 metabolizer status is associated with tamoxifen-related endocrine symptoms, tamoxifen discontinuation, and mammographic density change. PATIENTS AND METHODS: We used data from 1440 healthy women who participated the KARISMA dose determination trial. Endocrine symptoms were measured using a modified Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES) questionnaire. Change in mammographic density was measured and used as a proxy for tamoxifen response. Participants were genotyped and categorized as poor, intermediate, normal, or ultrarapid CYP2D6 metabolizers. RESULTS: The median endoxifen level per mg oral tamoxifen among poor, intermediate, normal and ultrarapid CYP2D6 metabolizers were 0.18 ng/ml, 0.38 ng/ml, 0.56 ng/ml and 0.67 ng/ml, respectively. Ultrarapid CYP2D6 metabolizers were more likely than other groups to report a clinically relevant change in cold sweats, hot flash, mood swings, being irritable, as well as the overall modified FACT-ES score, after taking tamoxifen. The 6-month tamoxifen discontinuation rates among poor, intermediate, normal, and ultrarapid CYP2D6 metabolizers were 25.7%, 23.6%, 28.6%, and 44.4%, respectively. Among those who continued and finished the 6-month tamoxifen intervention, the mean change in dense area among poor, intermediate, normal, and ultrarapid CYP2D6 metabolizers were -0.8 cm2, -4.5 cm2, -4.1 cm2, and -8.0 cm2 respectively. CONCLUSIONS: Poor CYP2D6 metabolizers are likely to experience an impaired response to tamoxifen, measured through mammographic density reduction. In contrast, ultrarapid CYP2D6 metabolizers are at risk for exaggerated response with pronounced adverse effects that may lead to treatment discontinuation.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. He W, Eriksson M, Eliasson E, et al. CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial. Ann Oncol. 2021. PMID: 34284099. doi:10.1016/j.annonc.2021.07.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。